EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates continues its coverage of Nymox Pharmaceutical
Corporation (Nasdaq:NYMX) reiterating its rating of Speculative Buy and
12-month price target of $6.25. The 10-page report by Dutton Associates
senior analyst William R. Prather, R.Ph., M.D. is available at www.jmdutton.com
as well as from First Call, Bloomberg, Zacks, Reuters, and Knobias and
other leading financial portals. We believe Nymox is still significantly
undervalued when one considers the multi-billion dollar benign prostatic
hyperplasia (BPH) market for NX-1207, the impressive clinical results to
date for the drug compared to standard therapeutic regimens on the
market today, and the market value of Nymox compared to similar
companies.
About Dutton Associates
Dutton Associates is one of the largest independent investment research
firms in the U.S. Its 28 senior analysts are primarily CFAs and have
expertise in many industries. Dutton Associates provides continuing
analyst coverage of 140 enrolled companies, and its research, estimates,
and ratings are carried in all the major databases serving institutions
and online investors.
The current cost of enrollment in our one-year continuing research
program is US $39,500 prepaid for 4 Research Reports, typically
published quarterly, and requisite Research Notes. Dutton Associates
received $57,500 from the Company for 4 Research Reports with coverage
commencing on 3/26/03. The Firm does not accept any equity compensation.
Our principals and analysts are prohibited from owning or trading in
securities of covered companies. The views expressed in this research
report accurately reflect the analyst's personal views about the subject
securities or issuer. Neither the analyst's compensation nor the
compensation received by us is in any way related to the specific
ratings or views contained in this research report or note. Please read
full disclosures and analyst background at www.jmdutton.com
before investing.
